Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kiniksa Pharmaceuticals International (KNSA) Accumulated Depreciation & Amortization (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Accumulated Depreciation & Amortization readings, the most recent being $7.4 million for Q1 2026.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 5.21% to $7.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $7.4 million, a 5.21% decrease, with the full-year FY2025 number at $7.2 million, down 11.75% from a year prior.
  • Accumulated Depreciation & Amortization hit $7.4 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $7.2 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $8.2 million in Q4 2024 to a low of $6.3 million in Q1 2022.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $7.7 million (2023), compared with a mean of $7.4 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: increased 24.98% in 2022 and later decreased 11.75% in 2025.
  • Kiniksa Pharmaceuticals International's Accumulated Depreciation & Amortization stood at $6.9 million in 2022, then increased by 13.5% to $7.8 million in 2023, then grew by 5.24% to $8.2 million in 2024, then decreased by 11.75% to $7.2 million in 2025, then increased by 1.99% to $7.4 million in 2026.
  • The last three reported values for Accumulated Depreciation & Amortization were $7.4 million (Q1 2026), $7.2 million (Q4 2025), and $7.8 million (Q3 2025) per Business Quant data.